Abstract Details

Title Determinants of quality of life in a large, online cohort of individuals with Parkinson’s disease

Topic Movement Disorders

Presentation(s) Movement Disorders Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 054

Objective To evaluate determinants of quality of life (QOL) in a large, online cohort of individuals with Parkinson’s Disease (PD).

Background PD is a multisystem, progressive illness with a variable clinical presentation, but few studies have investigated the key determinants of QOL in large populations. The Fox Insight study is a diverse online cohort that provides a unique opportunity to understand the experience of PD from the patient’s perspective.

Design/Methods As part of an ongoing cohort study, we performed a cross-sectional analysis to investigate contributors to health-related QOL. QOL was measured by the EQ-5D-5L tool indexed to US population norms (ranging from worst QOL at -0.6 and best at 1). We then conducted univariate and backwards stepwise multiple linear regression analyses of QOL. Forced variables included age, sex, race, and years with PD. Candidate variables included motor symptoms (MDS-UPDRS part II), non-motor symptoms (NMS Quest-PD), depression (Geriatric Depression Scale), subjective cognitive function (PDAQ-15), number of medical comorbidities, educational level, income, and type of diagnosing provider. Statistical significance was set at p=0.05 for inclusion in the model.

Results In the cohort (n=23,174), health-related QOL varied significantly by disease duration, income, and race in univariate analyses (p<0.001 for all). In the multivariate linear regression model, statistically significant predictors of worse QOL included higher number of medical comorbidities (beta=-0.14), more severe motor symptoms (beta=-0.54), more non-motor symptoms (beta=-0.06), depressive symptoms (beta=-0.24), and lower income (beta=0.05 for >$35,000 compared to <$35,000; p<0.05 for all). Self-reported cognition, educational level, and type of diagnosing provider were not significantly correlated with QOL.

Conclusions Motor and non-motor symptoms, particularly depression, account for a large amount of variation in QOL in patients with PD. Participant-reported outcomes administered online are an effective way to measure and track these associations. Understanding determinants of QOL is an essential first step in order to target its improvement.

Authors/Disclosures
Meredith Bock, MD (UCSF Center for Surgical Movement Disorders) PRESENTER	The institution of Dr. Bock has received research support from �鶹��ýӳ��. The institution of Dr. Bock has received research support from Michael J Fox Foundation.
Ethan G. Brown, MD (University of California, San Francisco)	Dr. Brown has received personal compensation in the range of $0-$499 for serving as a Consultant for Rune Labs, Inc. An immediate family member of Dr. Brown has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Brown has received personal compensation in the range of $0-$499 for serving as a Consultant for Guidepoint Inc. An immediate family member of Dr. Brown has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Brown has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NEJM Knowledge Plus. Dr. Brown has stock in 153 Therapeutics. The institution of Dr. Brown has received research support from Michael J. Fox Foundation. The institution of Dr. Brown has received research support from NIH.
Ethan G. Brown, MD (University of California, San Francisco)	Dr. Brown has received personal compensation in the range of $0-$499 for serving as a Consultant for Rune Labs, Inc. An immediate family member of Dr. Brown has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Brown has received personal compensation in the range of $0-$499 for serving as a Consultant for Guidepoint Inc. An immediate family member of Dr. Brown has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Brown has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NEJM Knowledge Plus. Dr. Brown has stock in 153 Therapeutics. The institution of Dr. Brown has received research support from Michael J. Fox Foundation. The institution of Dr. Brown has received research support from NIH.
Ethan G. Brown, MD (University of California, San Francisco)	Dr. Brown has received personal compensation in the range of $0-$499 for serving as a Consultant for Rune Labs, Inc. An immediate family member of Dr. Brown has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Brown has received personal compensation in the range of $0-$499 for serving as a Consultant for Guidepoint Inc. An immediate family member of Dr. Brown has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Brown has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NEJM Knowledge Plus. Dr. Brown has stock in 153 Therapeutics. The institution of Dr. Brown has received research support from Michael J. Fox Foundation. The institution of Dr. Brown has received research support from NIH.

�鶹��ýӳ��

�鶹��ýӳ��